» Articles » PMID: 31414610

Immunity, Hypoxia, and Metabolism-the Ménage à Trois of Cancer: Implications for Immunotherapy

Overview
Journal Physiol Rev
Specialty Physiology
Date 2019 Aug 16
PMID 31414610
Citations 161
Authors
Affiliations
Soon will be listed here.
Abstract

It is generally accepted that metabolism is able to shape the immune response. Only recently we are gaining awareness that the metabolic crosstalk between different tumor compartments strongly contributes to the harsh tumor microenvironment (TME) and ultimately impairs immune cell fitness and effector functions. The major aims of this review are to provide an overview on the immune system in cancer; to position oxygen shortage and metabolic competition as the ground of a restrictive TME and as important players in the anti-tumor immune response; to define how immunotherapies affect hypoxia/oxygen delivery and the metabolic landscape of the tumor; and vice versa, how oxygen and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and clinical endeavors, we will discuss how a metabolic characterization of the TME can identify novel targets and signatures that could be exploited in combination with standard immunotherapies and can help to predict the benefit of new and traditional immunotherapeutic drugs.

Citing Articles

The Complexity of Malignant Glioma Treatment.

Kampers L, Metselaar D, Vinci M, Scirocchi F, Veldhuijzen van Zanten S, Eyrich M Cancers (Basel). 2025; 17(5).

PMID: 40075726 PMC: 11899524. DOI: 10.3390/cancers17050879.


POU2F2 B cells enhance antitumor immunity and predict better survival in non small cell lung cancer.

Shi H, Wang W, Luo J, Song G, Han R Sci Rep. 2025; 15(1):6549.

PMID: 39994401 PMC: 11850725. DOI: 10.1038/s41598-025-90817-3.


Histone lactylation-driven B7-H3 expression promotes tumor immune evasion.

Ma Z, Yang J, Jia W, Li L, Li Y, Hu J Theranostics. 2025; 15(6):2338-2359.

PMID: 39990209 PMC: 11840737. DOI: 10.7150/thno.105947.


Hypoxia-induced S-phase kinase-interacting protein 2 knockdown repressed the progression of melanoma through extracellular signal-regulated kinase 1/2 pathway.

Hu Y Cytojournal. 2025; 22:9.

PMID: 39958883 PMC: 11829309. DOI: 10.25259/Cytojournal_117_2024.


Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC.

Li C, Zhang E, Yu R, Yuan B, Yang Y, Zeng Z Transl Oncol. 2025; 53:102314.

PMID: 39904279 PMC: 11846587. DOI: 10.1016/j.tranon.2025.102314.